ERBB3 and neoplasm: The HER3-specific binding ligand of HPK is derived from a minimal binding domain of neuregulin-1⍺1 [96] which, in comparison to neuregulin-1β1, appears to partially abrogate the activation of HER3 on tumor cells [22].